US-based biotechnology company Exelixis has signed a clinical trial collaboration agreement with Arcus Biosciences to analyse zanzalintinib along with AB521 in a Phase Ib/II clinical trial.
The combination therapy will be assessed for advanced solid tumours, including clear cell renal cell carcinoma.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The open-label STELLAR-009 trial will determine the recommended dose of zanzalintinib with AB521 in its dose-finding stage.
Sponsored by Exelixis and jointly funded by Arcus, the trial is due to begin enrolling subjects before the end of this year.
Exelixis product development AND medical affairs executive vice-president and chief medical officer Amy Peterson said: “We are excited to learn more about the potential effects of zanzalintinib plus Arcus’ HIF-2⍺ inhibitor, as these two molecules approach the inhibition of cancer cell proliferation and tumour angiogenesis from differing angles, and combination therapy may provide better outcomes than either therapy alone.
“We have a long-established commitment to advancing treatment options in kidney cancer, and we are eager to maximise the potential of zanzalintinib through this collaboration with Arcus and look forward to advancing the combination in the clinic.”
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataZanzalintinib is a tyrosine kinase inhibitor (TKI) that hinders the functioning of receptor tyrosine kinases associated with the growth and spread of cancer.
It is in development to potentially treat various advanced solid tumours such as colorectal, genitourinary and head and neck cancers.
Arcus Biosciences chief medical officer Dimitry Nuyten said: “We are excited to partner with Exelixis on the STELLAR-009 study to determine the best-in-class potential of AB521 in combination with zanzalintinib and look forward to generating a robust set of data to move this combination into full development.
“The STELLAR-009 study is an important step in the development of AB521 and enables a cost-effective path to evaluating our HIF-2⍺ inhibitor with a next-generation TKI.”
